Bronchiolitis Obliterans Syndrome Pipeline Insight Report 2019 - ResearchAndMarkets.com

DUBLIN--()--The "Bronchiolitis Obliterans Syndrome Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Bronchiolitis Obliterans Syndrome (BOS) - Pipeline Insight, 2019 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Bronchiolitis Obliterans Syndrome (BOS) pipeline landscape is provided which includes the disease overview and Bronchiolitis Obliterans Syndrome (BOS) treatment guidelines.

The assessment part of the report embraces, in depth Bronchiolitis Obliterans Syndrome (BOS) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Bronchiolitis Obliterans Syndrome (BOS) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Bronchiolitis Obliterans Syndrome (BOS) Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Bronchiolitis Obliterans Syndrome (BOS) targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available.

Bronchiolitis Obliterans Syndrome (BOS) pipeline report covers 9+ companies. Some of the key players include Incyte Corporation (Itacitinib), PARI Pharma (Ciclosporin liposomal), Mereo BioPharma (Alvelestat) etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Bronchiolitis Obliterans Syndrome (BOS) Analytical Perspective

In-depth Bronchiolitis Obliterans Syndrome (BOS) Commercial Assessment of products

This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition -Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.

Bronchiolitis Obliterans Syndrome (BOS) Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Key Topics Covered:

1. Report Introduction

2. Bronchiolitis Obliterans Syndrome (BOS)

2.1. Bronchiolitis Obliterans Syndrome (BOS) Disease Overview

2.2. Bronchiolitis Obliterans Syndrome (BOS) History

2.3. Bronchiolitis Obliterans Syndrome (BOS) Symptoms

2.4. Bronchiolitis Obliterans Syndrome (BOS) Causes

2.5. Bronchiolitis Obliterans Syndrome (BOS) Pathophysiology

2.6. Bronchiolitis Obliterans Syndrome (BOS) Diagnosis

3. Bronchiolitis Obliterans Syndrome (BOS) Current Treatment Patterns

3.1. Treatment Guidelines

4. Bronchiolitis Obliterans Syndrome (BOS)- Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Bronchiolitis Obliterans Syndrome companies collaborations, Licensing, Acquisition -Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Bronchiolitis Obliterans Syndrome Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing/Partnering) Analysis

4.1.2.2. Bronchiolitis Obliterans Syndrome (BOS) Acquisition Analysis

4.2. Clinical Assessment of Pipeline Drugs

4.2.1. Assessment by Phase of Development

4.2.2. Assessment by Product Type (Mono/Combination)

4.2.2.1. Assessment by Stage and Product Type

4.2.3. Assessment by Route of Administration

4.2.4. Assessment by Molecule Type

4.2.5. Assessment by MOA

5. Bronchiolitis Obliterans Syndrome Pipeline Therapeutics

5.1. Late Stage Products (Phase-III)

5.1.1. Comparative Analysis

5.2. Mid Stage Products (Phase-II)

5.3. Early Stage Products (Phase-I)

5.4. Pre-clinical and Discovery Stage Products

5.5. Inactive Products

6. Bronchiolitis Obliterans Syndrome -Products Analysis

6.1. Product Profiles

6.1.1. Itacitinib- Incyte Corporation

6.1.2. Ciclosporin liposomal- PARI Pharma

6.1.3. Alvelestat - Mereo BioPharma

7. Recent Technologies

8. Bronchiolitis Obliterans Syndrome (BOS) Key Companies

8.1. Novartis

8.2. PARI Pharma

8.3. Gilead Sciences

8.4. Roche

8.5. Alnylam Pharmaceuticals

8.6. Abbott

8.7. Incyte Corporation

8.8. Mereo BioPharma

8.9. Novus Biologicals

9. Bronchiolitis Obliterans Syndrome Key Products

9.1. Aerosolised ciclosporin

9.2. Ciclosporin liposomal

9.3. Aztreonam inhalation

9.4. Asvasiran sodium

9.5. Everolimus

9.6. Ruxolitinib

9.7. Alvelestat

9.8. Uteroglobin

9.9. Itacitinib

9.10. Pirfenidone

10. Dormant and Discontinued Products

10.1. Dormant Products

10.1.1. Reasons for being dormant

10.2. Discontinued Products

10.2.1. Reasons for the discontinuation

11. Bronchiolitis Obliterans Syndrome - Unmet Needs

12. Bronchiolitis Obliterans Syndrome - Future Perspectives

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/xbbg5x

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900